Compounding evidence: management cites customer behavior, not just customer numbers, as proof the offering is winning
The model's full reasoning — Q3 2021 call → NOWe need to determine if management grounds its case in observed customer or counterparty behavior from the recent period, described concretely and currently, and treats that behavior as core proof with more ahead. Let's examine the transcript. Management discusses vadadustat, Auryxia, partnerships, etc. They talk about market opportunity, data, launch preparations, but do they cite specific recent behavior of customers or counterparties? For example, they mention that in Japan, the HIF-PHI share of the anemia market continues to grow, and more physicians in Japan have stated intention to prescribe HIF-PHIs over ESAs. That is a concrete behavior: physicians' stated intention, market share growth. But is that recent? They say "continues to grow" and "more physicians in Japan have stated an intention" - that is observed behavior. However, is that central to their case? They mention it as encouraging, but the main case is about US launch preparation. They also mention the Vifor distribution relationship, which is a partnership, but that's not a recent behavior of customers. They talk about Auryxia revenue growth, but that's their own results. They mention that the team is preparing, but no specific customer behavior like reorders, adoption, etc. The only concrete behavior is the Japan market share growth and physician intention, but that is from their partner's launch, not their own recent period? It is recent, but is it central? They say "We are encouraged that the HIF-PHI share of the anemia market continues to grow in Japan, along with VASFSEO market share. And that more physicians in Japan have stated an intention to prescribe HIF-PHIs over ESAs." That is a concrete behavior, but it's about the class, not specifically vadadustat? It is about HIF-PHIs, which includes vadadustat. But is it described as observed now? Yes. However, is it treated as core proof for the company's growth? They mention it as part of global potential, but the main focus is US launch. They also mention the UT Health study expansion, but that's a clinical trial, not customer behavior. They mention the EMA submission, but that's regulatory.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| AIRG | Airgain, Inc. | Q3 2023 | 2023-11-09 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| AWRE | Aware, Inc. | Q3 2022 | 2022-10-30 | F |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
ULCC · Q1 2023 → YESThe question is: Does management ground their case in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management points to concrete recent-period behavior: over half of GoWild Pass sales so far are from customers with no prior travel history with Frontier, plus overwhelmingly positive feedback and customers taking the product to social media. They treat this observed adoption pattern as central proof that the offering is working and will keep growing, with the 90%+ repeat rate and $85–$100 per-passenger contribution goals still ahead of current results. They also cite the shift in consumer demand patterns (leisure travel increasingly favoring peak days, expanding RASM premium from 19% to over 25%) as direct evidence of customer preference that is reshaping capacity and margins. These elements are presented as the behavioral foundation for continued growth rather than merely company results or plans.
PCRX · Q4 2017 → YESThe question is: Does management ground their case for why the business is working and will keep growing in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management grounds its case in concrete, observed counterparty behavior—specifically J&J’s sales team activating accounts and training customers on EXPAREL technique, with the number of activated accounts continuing to grow, plus J&J committing to a six-fold increase in PEAK programs (already exceeding 2018 plans). They also cite commercial payers paying for EXPAREL under C9290 as a medical benefit and hospitals gaining access through surgeon relationships, treating these patterns as central proof that the offering is being chosen and valued, with the business still early and expanding ahead.
PPC · Q1 2024 → YESThe question is: Does management ground their case in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management grounds its case in observed counterparty behavior by citing concrete patterns such as key customers increasing marketplace presence, deli and QSRs showing steady performance, brands growing faster than category averages in Europe, key customer partnerships driving growth in Mexico, and key customers outpacing industry growth in domestic chicken volumes and value-added products — all presented as recent, specific actions by buyers and partners that demonstrate genuine preference and commitment, with the business still building further through continued diversification and new opportunities.